This trial will compare the effectiveness of asciminib versus another treatment for newly diagnosed patients with a certain type of blood cancer.
- Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
1 Primary · 32 Secondary · Reporting Duration: Planned total follow-up duration of 5 years
2 Treatment Groups
Investigator selected TKIs
1 of 2
1 of 2
402 Total Participants · 2 Treatment Groups
Primary Treatment: Asciminib · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Has the FDA sanctioned Asciminib for public use?
"Asciminib falls into our "safe" category, with a 3/3 score. This is because it's a Phase 3 trial, meaning that there is not just some data supporting efficacy, but multiple rounds of data confirming its safety." - Anonymous Online Contributor
What has been the medical community's response to Asciminib thus far?
"Presently, there are one-hundred and forty different studies investigating Asciminib with twenty-nine in Phase 3. Many of the tests for this medication are taking place in Montreal, Quebec; however, 5884 other areas around the world are also running similar research." - Anonymous Online Contributor
What has Asciminib been shown to be an effective treatment for?
"Refractory [acute lymphoblastic leukemia](https://www.withpower.com/clinical-trials/acute-lymphoblastic-leukemia) (ALL) is most commonly treated with the medication asciminib. This drug is also used to manage other conditions, such as chordomas, blast phase, and refractory chronic phase chronic myeloid leukemia." - Anonymous Online Contributor